読み込み中
HKSEHealthcareMedical - Devices
最新データ
HK$5.89
+HK$0.01 · +0.17%
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
最新データ
HK$5.89
+HK$0.01 · +0.17%
日中の時刻はHKTです。市場データは遅延する場合があります。
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
日中レンジ
現在 HK$5.89
52週レンジ
現在 HK$5.89
日中の時刻はHKTです。市場データは遅延する場合があります。
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
日中レンジ
現在 HK$5.89
52週レンジ
現在 HK$5.89
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.45億 CNY | 5.34億 CNY | 4.74億 CNY | 3.96億 CNY | 3.04億 CNY |
| 売上原価 | 1.68億 CNY | 1.31億 CNY | 9643.3万 CNY | 5919.2万 CNY | 3787.4万 CNY |
| 粗利益 | 4.76億 CNY | 4.03億 CNY | 3.77億 CNY | 3.36億 CNY | 2.66億 CNY |
| 研究開発 | 2.14億 CNY | 2.17億 CNY | 1.9億 CNY | 1.84億 CNY | 1.41億 CNY |
| 販売・一般管理 | 1.82億 CNY | 1.58億 CNY | 1.81億 CNY | 1.61億 CNY | 1.58億 CNY |
| 営業費用 | 3.43億 CNY | 3.39億 CNY | 3.52億 CNY | 2.64億 CNY | 2.03億 CNY |
| 受取利息 | 2566.6万 CNY | 3014.7万 CNY | 1850.5万 CNY | 2025.8万 CNY | 472.5万 CNY |
| 支払利息 | 938.5万 CNY | 1150.4万 CNY | 983.3万 CNY | 141.5万 CNY | 382.4万 CNY |
| 減価償却費と償却費 | 5364.4万 CNY | 4998万 CNY | 4625.8万 CNY | 1944万 CNY | 1240.3万 CNY |
| 営業利益 | 1.33億 CNY | 6400.7万 CNY | 2500.9万 CNY | 7207.5万 CNY | 6341.9万 CNY |
| 純利益 | 1.19億 CNY | 5228万 CNY | 1448.7万 CNY | 7014.2万 CNY | −7907.7万 CNY |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
